The Safety and Efficacy of a Paclitaxel-eluting Wrap for Preventing Peripheral Bypass Graft Stenosis: A 2-Year Controlled Randomized Prospective Clinical Study

European Journal of Vascular and Endovascular Surgery

Volumn 35, Issue 6, 2008, Pages 715-722

  Matyas L ^a   Berry, M ^b   Menyhei, G ^c   Tamas L ^d   Acsady G ^e   Cuypers, P ^f   Halmos, F ^g   de Vries, A C ^h   Forgacs, V ⁱ   Ingenito, G ^j   Avelar, R ^j  

^a Borsod County Teaching Hospital   (Hungary)

^b St Elisabeth Hospital Willemstad   (Netherlands Antilles)

^c UNIVERSITY OF PÉCS   (Hungary)

^d Endocrinology and Diabetology   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f CATHARINA HOSPITAL   (Netherlands)

^g Kaposvár County Hospital   (Hungary)

^h MEDICAL CENTER HAAGLANDEN   (Netherlands)

ⁱ Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^j Angiotech Pharmaceuticals Inc   (Canada)

more..

Author keywords

Bypass; Grafting; Occlusion; Peripheral vascular disease; Stenosis

Indexed keywords

PACLITAXEL; POLITEF;

ADULT; ARTICLE; BLOOD VESSEL GRAFT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMOROPOPLITEAL BYPASS; GRAFT INFECTION; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOSIS;

AMPUTATION; ANASTOMOSIS, SURGICAL; BANDAGES; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR AGENTS; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; MALE; MIDDLE AGED; NETHERLANDS ANTILLES; PACLITAXEL; PERIPHERAL VASCULAR DISEASES; POLYTETRAFLUOROETHYLENE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REOPERATION; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 43749110672     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.11.024     Document Type: Article

References (22)

1. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. Peripheral arterial disease: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). J Am Coll Cardiol 47 (2006) 1239-1312
2. Allie D.E., Hebert C.J., Lirtzman M.D., Wyatt C.H., Keller V.A., Khan M.H., et al. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. EuroIntervention 1 (2005) 75-84
3. Dormandy J.A., Rutherford R.B., and for the TASC Working Group. Management of peripheral arterial disease (PAD); Transatlantic Inter-Society Consensus (TASC). J Vasc Surg 31 1 Pt 2 (2000) S1-S296
4. Mamode N., and Scott R.N. Graft type for femoropopliteal bypass surgery. Cochrane Database Syst Rev 2 (2000) CD001487
5. Lemson M.S., Tordoir J.H.M., van Det R.J., Welten R.J.Th.J., Burger H., Estourgie R.J.A., et al. Effects of a venous cuff at the venous anastomosis of polytetrafluoroethylene grafts for hemodialysis vascular access. J Vasc Surg 32 (2000) 1155-1163
6. Klinkert P., Schepers A., Burger D.H.C., van Bockel J.H., and Breslau P.J. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg 37 (2003) 149-155
7. Clowes A.W. Intimal hyperplasia and graft failure. Cardiovasc Pathol 2 Suppl (1993) 179S-186S
8. Lemson M.S., Tordoir J.H.M., Daeman M.J.A.P., and Kitslaar P.J.E.H.M. Intimal hyperplasia in vascular grafts. Eur J Vasc Endovasc Surg 19 (2000) 336-350
9. Sollott S.J., Cheng L., Pauly R.R., Jenkins G.M., Monticone R.E., Kuzuya M., et al. Taxol inhibits neointimal smooth muscle cells accumulation after angioplasty in the rat. J Clin Invest 95 (1995) 1869-1876
10. Axel D.I., Kunert W., Goggelmann C., Oberhoff M., Herdeg C., Kuttner A., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
11. Farb A., Heller P.F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
12. Signore P.E., Machan L.S., Jackson J.K., Burt H., Bromley P., Wilson J.E., et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol 12 (2001) 79-88
13. Masaki T., Rathi R., Zentner G., Leypoldt J.K., Mohammad S.F., Burns G.L., et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 66 (2004) 2061-2069
14. Avelar R., and Toleikis P. Paclitaxel eluting mesh: a new weapon in fighting intimal hyperplasia. In: Chakfé N., Durand B., and Kretz J.-G. (Eds). New technologies in vascular biomaterials. Fundamentals of Stents II (2007), EUROPROT, Strasbourg 199-214
15. Kohler T.R., Toleikis P.M., Gravett D.M., and Avelar R.L. Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable Vascular Wrap™ paclitaxel-eluting mesh. J Vasc Surg 45 (2007) 1029-1038
16. Johnson K.K., Russ P.D., Bair J.H., and Friefeld G.D. Diagnosis of synthetic vascular graft infection: comparison of CT and gallium scans. AJR Am J Roentgenol 154 (1990) 405-409
17. Pounds L.L., Montes-Walters M., Mayhall C.G., Falk P.S., Sanderson E., Hunter G.C., et al. A changing pattern of infection after major vascular reconstructions. Vasc Endovasc Surg 39 (2005) 511-517
18. Pedersen G., Laxdal E., Hagala M., and Aune S. Local infections after above-knee prosthetic femoropopliteal bypass for intermittent claudication. Surg Infect (Larchmt) 5 (2004) 174-179
19. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., et al., for the TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
20. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al., on behalf of the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
21. Tornio A., Pasanen M.K., Laitila J., Neuvonen P.J., and Backman J.T. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochromes P450 2C8. Basic Clin Pharmacol Toxicol 97 (2005) 104-108
22. Most R.S., and Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 6 (1983) 87-91